Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0793
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2617
    -0.0005 (-0.04%)
     
  • USD/JPY

    151.3300
    -0.0420 (-0.03%)
     
  • Bitcoin USD

    70,227.82
    -600.40 (-0.85%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Abbott to vote for Mylan's acquisition of Perrigo

(Corrects to "off" from "of" in first paragraph)

June 16 (Reuters) - Mylan NV's largest stakeholder, Abbott Laboratories, said it would back Mylan's proposed acquisition of Perrigo Co Plc, potentially helping Mylan fend off interest from Teva Pharmaceutical Industries Ltd .

Abbott, which has a 14.5 percent stake in Mylan, said on Tuesday that it supported Mylan's "standalone strategy" and believed acquiring Perrigo would add value for shareholders.

Mylan's latest offer for Perrigo, worth $34.1 billion, is widely seen as an attempt to fend off Teva, the world's biggest maker of generic drugs.

Perrigo rejected Mylan's sweetened offer in late April, around the same time Mylan rejected an offer of $40 billion from Teva, saying it grossly undervalued the company.

Last year, Mylan said it would buy Abbott's branded specialty and generics business in developed markets outside the United States in a $5.3 billion deal that would bolster its product line and cut its tax bill.

The deal gave Mylan an array of Abbott brands with sales of almost $2 billion, while Abbott received 105 million shares of the combined company, renamed Mylan NV.

Mylan's shares were down 2.1 percent at $72 in early trading. Perrigo's shares were up about 3 percent at $188.62, while Teva's stock was little changed.

(Reporting by Amrutha Penumudi in Bengaluru; Editing by Joyjeet Das and Simon Jennings)

Advertisement